Petru Zurzu
Fluorescence-Guided Surgery (FGS) has emerged as a promising technique for enhancing intraoperative visualization and precision in tumor resection. Monoclonal Antibodies (mAbs) offer a targeted approach to FGS, facilitating the selective binding of fluorescent probes to tumor-specific antigens. In this review, we explore the applicability of mAbs in FGS across various solid tumors. We systematically analyze recent literature to evaluate the efficacy and safety of mAb-based FGS strategies in different tumor types, including breast cancer, colorectal cancer, glioblastoma, and others. Key aspects such as target selection, fluorescent probe conjugation, imaging modalities, and clinical outcomes are discussed. Furthermore, we address challenges and limitations associated with the clinical translation of mAb-based FGS, including antigen heterogeneity, probe pharmacokinetics, and regulatory considerations. Strategies for overcoming these hurdles and optimizing mAb-based FGS for broader clinical utility are proposed. Overall, this review highlights the potential of monoclonal antibodies as valuable tools for improving surgical outcomes in solid tumor resection through enhanced intraoperative visualization and precise tumor targeting. This abstract provides a brief overview of the review's scope, methodologies, key findings, and implications, giving readers an insight into the content covered in the full review.
Teile diesen Artikel